The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates

J Neuroimmunol. 2010 Jun;223(1-2):138-40. doi: 10.1016/j.jneuroim.2010.03.022. Epub 2010 Apr 24.

Abstract

Anakinra improves the central nervous system manifestations of neonatal-onset multisystem inflammatory disease, which is mediated by IL-1beta oversecretion. The cerebrospinal fluid (CSF) penetration of the IL-1 receptor antagonist anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg. Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum. The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Interleukin 1 Receptor Antagonist Protein / administration & dosage*
  • Interleukin 1 Receptor Antagonist Protein / blood
  • Interleukin 1 Receptor Antagonist Protein / cerebrospinal fluid
  • Interleukin 1 Receptor Antagonist Protein / pharmacokinetics*
  • Interleukin 1 Receptor Antagonist Protein / standards
  • Macaca mulatta
  • Male

Substances

  • Interleukin 1 Receptor Antagonist Protein